The discovery that sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) reduce the risk of cardiovascular and kidney disease in patients with type 2 diabetes (T2D) has had a substantial effect on clinical practice. Here, SLC5A2 is linked to type 2 diabetes mellitus.